Federal contradiction
A bill that would eliminate the majority of CBD-based products from sale is also being proposed.
In just two weeks, Trump signed, on the 12th of November, a federal funding bill which is expected to define hemp as per federal law. This could have a devastating effect on the industry.Â
The legislation prohibits ‘any intermediate hemp-derived cannabinoid products containing more than 0.3% combined total of total tetrahydrocannabinols and any other cannabinoids that have similar effects.’
It is effective November 13, 2026. That gives the industry time to make necessary adjustments.Â
The critical problem is that, during the extraction and distillation process, nearly all CBD crudes and distillates routinely surpass 0.3% THC total on a mass basis even though the final product comes in well under the maximum limit.
These intermediate materials will be classified as controlled substances under the new definition. This makes it impossible to produce CBD legally using existing processes.
CMS acknowledged this contradiction, noting that hemp products meeting the current 2018 definition remain legal ‘through November 11th, 2026,’ with those meeting the amended definition remaining legal thereafter.
So, medicare only covers CBD products for a short time before the potential of making them illegal.
“Instead of creating clarity and responsible regulation for hemp-derived products, this ban destabilises an entire sector that has generated jobs, tax revenue, and safe access for millions of Americans,” said Jasmine Johnson, CEO of GŪD Essence.
It only drives consumers to unregulated markets.
Paula Savchenko, founding partner of Cannacore Group and PS Law Group, warned that ‘the hemp sector may begin to resemble the cannabis market, with a fragmented supply chain cut off from the benefits of interstate commerce.’
The American Council of Cannabis Medicine (ACCM) announced in October a national initiative, with major insurance companies and healthcare systems. Its goal is to broaden access to medical cannabis.
Over 400 associations have joined the program and gained access to patient referral network.
Sasha Kalcheff Korn, the executive director of Realm of Caring and a patient advocate, welcomed Medicare’s policy, but cautioned: “Without an established federal regulatory pathway within the next eleven months, millions of Americans could lose their access to these products.”
Sponsored Content
This informative article is brought to you by Gen-Europa →
Federal contradiction
A bill that would eliminate the majority of CBD-based products from sale is also being proposed.
In just two weeks, Trump signed, on the 12th of November, a federal funding bill which is going to redefine hemp lawfully in ways that will devastate this industry.Â
The legislation prohibits ‘any intermediate hemp-derived cannabinoid products containing more than 0.3% combined total of total tetrahydrocannabinols and any other cannabinoids that have similar effects.’
This provision will come into effect on November 13th, 2026. The industry has some time to adjust.Â
The critical problem is that, during the extraction and distillation process, nearly all CBD crudes and distillates routinely surpass 0.3% THC total on a mass basis even though the final product comes in well under the maximum limit.
These intermediate materials will be classified as controlled substances under the new definition. This makes it impossible to produce CBD legally using existing processes.
CMS acknowledged this contradiction, noting that hemp products meeting the current 2018 definition remain legal ‘through November 11th, 2026,’ with those meeting the amended definition remaining legal thereafter.
Medicare will only cover CBD-based products for a little over a year, before the manufacture of these products could become illegal.
“Instead of creating clarity and responsible regulation for hemp-derived products, this ban destabilises an entire sector that has generated jobs, tax revenue, and safe access for millions of Americans,” said Jasmine Johnson, CEO of GŪD Essence.
It only drives consumers to unregulated markets.
Paula Savchenko, founding partner of Cannacore Group and PS Law Group, warned that ‘the hemp sector may begin to resemble the cannabis market, with a fragmented supply chain cut off from the benefits of interstate commerce.’
The American Council of Cannabis Medicine, in October announced an initiative to increase access to medical marijuana. This was a joint effort with the major healthcare providers and insurers.
Over 400 associations have joined the program and gained access to patient referral network.
Sasha Kalcheff Korn, the executive director of Realm of Caring and a patient advocate, welcomed Medicare’s policy, but cautioned: “If there is not a federally-regulated pathway in place for these products by the end of the year, millions of Americans could be denied access to them.”
Sponsored Content
This informative article is brought to you by Gen-Europa →
Cannabis Law Resources for Poland
Browse essential legal pages on cannabis sales and cultivation in Poland. You can use these resources to learn about the requirements for certification, permissions and compliance.
-
Polish News Registration and Interests of Cannabis Businesses
-
Permissions for Cannabis Sales in Poland
-
Authorization for Importing or Manufacturing Medical Products
-
Permission for Manufacturing or Importing Medical Products
-
Certificate of Good Manufacturing Practices (GMP)
-
Registration of Medical Products in Poland